American Heart Journal
Volume 158, Issue 5 , Pages 784.e1-784.e6 , November 2009

The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy

Received 15 June 2009 ,Accepted 14 August 2009.

References 

  1. Centers for Disease Control and Prevention . National diabetes fact sheet, United States, 2005. Available at: http://apps.nccd.cdc.gov/DDTSTRS/template/ndfs_2005.pdf2009;Last accessed March 15
  2. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  3. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: National Diabetes Data Group  editors. 2nd ed. Diabetes in America. Bethesda, MD: National Institutes of Health; 1995;p. 429–448NIH publication 95-1468
  4. Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res. 2008;5:138–144
  5. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181–2188
  6. DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007;56:3014–3019
  7. Saucedo JF, Singla A, Mauer K, et al. Reduced anti-platelet response to clopidogrel in diabetic patients undergoing percutaneous coronary intervention. Circulation. 2008;118:819
  8. American Diabetes Association . Standards of medical care in diabetes—2006. Diabetes Care. 2006;29:S4–42
  9. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol. 2005;46:1820–1826
  10. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908–2913
  11. American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29:S43–48
  12. Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets. 2008;19:595–604
  13. Grant PG. Diabetes mellitus as a prothrombotic condition. J Int Med. 2007;262:157–172
  14. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282–1291
  15. Demirtunc R, Duman D, Basar M, et al. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complications. 2009;23:89–94
  16. Angiolillo DJ, Bernardo E, Ramírez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006;48:298–304
  17. Angiolillo DJ, Bernardo E, Sabaté M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50:1541–1547
  18. Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol. 2004;43:8–14

PII: S0002-8703(09)00640-1

doi: 10.1016/j.ahj.2009.08.013

American Heart Journal
Volume 158, Issue 5 , Pages 784.e1-784.e6 , November 2009

Article Tools

* Image Usage & Resolution